Processa Pharmaceuticals, Inc.
PCSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7,269 | $5,800 | $11,494 | $6,878 |
| G&A Expenses | $4,782 | $5,658 | $8,763 | $4,689 |
| SG&A Expenses | $4,782 | $5,658 | $8,763 | $4,689 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $7,268 | $567 |
| Operating Expenses | $12,051 | $11,457 | $27,525 | $12,134 |
| Operating Income | -$12,051 | -$11,457 | -$27,525 | -$12,134 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $201 | $336 | $101 | $175 |
| Pre-Tax Income | -$11,850 | -$11,122 | -$27,424 | -$11,958 |
| Tax Expense | $0 | $0 | $0 | -$531 |
| Net Income | -$11,850 | -$11,122 | -$27,424 | -$11,428 |
| % Margin | – | – | – | – |
| EPS | -96.75 | -212 | -42.5 | -373 |
| % Growth | 54.4% | -398.8% | 88.6% | – |
| EPS Diluted | -96.75 | -212 | -42.5 | -373 |
| Weighted Avg Shares Out | 122 | 52 | 32 | 31 |
| Weighted Avg Shares Out Dil | 122 | 52 | 32 | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | $201 | $336 | $101 | $12 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $788 | $791 |
| EBITDA | -$12,050 | -$11,457 | -$19,469 | -$10,776 |
| % Margin | – | – | – | – |